Safety and performance of the EverProTM everolimus-eluting coronary stent system with biodegradable polymer in a real-world scenario

Table 2 Procedural and lesion characteristics

Characteristics	n = 77
Access site approach, n (%)
Femoral	20 (26)
Radial	57 (74)
Total number of lesions	102
Total number of lesions treated with EverProTM	98
Lesions per patient	1.32
Stents per patient	1.27
Lesion location, n (%)
Right carotid artery	29 (29.6)
Left anterior descending artery	48 (49)
Left circumflex artery	12 (12.2)
Obtuse marginal artery	9 (9.2)
Stenosis type, n (%)
De novo	95 (96.9)
In-stent	3 (3.1)
Thrombus load, n (%)
None	76 (77.6)
Mild	10 (10.2)
Moderate	5 (5.1)
Severe	7 (7.1)
ACC/AHA lesion type, n (%)
A	5 (5.1)
B1	30 (30.6)
B2	38 (38.8)
C	25 (25.5)
Percent stenosis (mean ± SD)	88.39 ± 9.30
Stent length (mean ± SD), mm	18.20 ± 4.34
Stent diameter (mean ± SD), mm	2.89 ± 0.36
TIMI flow post-procedure, n (%)
TIMI 3	98 (100)
Discharge medications, n (%)
Aspirin	77 (100)
Clopidogrel	44 (57.1)
Ticlopidine	2 (2.6)
Prasugrel	3 (3.9)
Ticagrelor	27 (35.1)

ACC: American College of Cardiology; AHA: American Heart Association; SD: Standard deviation; TIMI: Thrombolysis in myocardial infarction.